Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives $78.60 Consensus Target Price from Brokerages

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) has been given a consensus rating of “Moderate Buy” by the fifteen research firms that are presently covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $77.93.

A number of research firms recently weighed in on APLS. Needham & Company LLC reaffirmed a “buy” rating and set a $85.00 target price on shares of Apellis Pharmaceuticals in a report on Tuesday, April 9th. Raymond James increased their price objective on Apellis Pharmaceuticals from $67.00 to $106.00 and gave the stock a “strong-buy” rating in a research report on Thursday, January 11th. UBS Group boosted their target price on Apellis Pharmaceuticals from $87.00 to $89.00 and gave the stock a “buy” rating in a research report on Monday, March 4th. Wedbush dropped their price target on Apellis Pharmaceuticals from $67.00 to $57.00 and set a “neutral” rating for the company in a research report on Wednesday. Finally, Mizuho reissued a “neutral” rating and set a $60.00 price objective on shares of Apellis Pharmaceuticals in a report on Wednesday, March 27th.

Apellis Pharmaceuticals Stock Performance

Shares of Apellis Pharmaceuticals stock opened at $48.03 on Monday. The firm has a market capitalization of $5.79 billion, a P/E ratio of -10.72 and a beta of 0.88. Apellis Pharmaceuticals has a 12 month low of $19.83 and a 12 month high of $94.75. The company has a current ratio of 3.10, a quick ratio of 2.50 and a debt-to-equity ratio of 0.48. The business’s fifty day simple moving average is $60.54 and its 200 day simple moving average is $57.04.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Tuesday, February 27th. The company reported ($0.73) EPS for the quarter, hitting analysts’ consensus estimates of ($0.73). The firm had revenue of $146.38 million during the quarter, compared to analyst estimates of $143.34 million. Apellis Pharmaceuticals had a negative return on equity of 178.60% and a negative net margin of 133.34%. The business’s revenue for the quarter was up 545.9% on a year-over-year basis. During the same period last year, the company earned ($1.50) earnings per share. As a group, analysts anticipate that Apellis Pharmaceuticals will post -1.33 EPS for the current year.

Insider Transactions at Apellis Pharmaceuticals

In related news, General Counsel David O. Watson sold 781 shares of Apellis Pharmaceuticals stock in a transaction on Monday, February 12th. The shares were sold at an average price of $67.77, for a total value of $52,928.37. Following the sale, the general counsel now owns 103,390 shares in the company, valued at $7,006,740.30. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Apellis Pharmaceuticals news, General Counsel David O. Watson sold 781 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $67.77, for a total transaction of $52,928.37. Following the sale, the general counsel now directly owns 103,390 shares of the company’s stock, valued at approximately $7,006,740.30. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Cedric Francois sold 250,000 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $64.11, for a total value of $16,027,500.00. Following the completion of the transaction, the chief executive officer now directly owns 313,662 shares of the company’s stock, valued at approximately $20,108,870.82. The disclosure for this sale can be found here. In the last three months, insiders have sold 406,651 shares of company stock worth $25,130,257. 7.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Large investors have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD grew its stake in shares of Apellis Pharmaceuticals by 66.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 4,590,040 shares of the company’s stock worth $302,760,000 after acquiring an additional 1,840,498 shares during the last quarter. Jennison Associates LLC increased its stake in Apellis Pharmaceuticals by 79.8% during the 3rd quarter. Jennison Associates LLC now owns 3,542,209 shares of the company’s stock valued at $134,746,000 after purchasing an additional 1,571,606 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in Apellis Pharmaceuticals by 109.6% in the fourth quarter. Assenagon Asset Management S.A. now owns 2,145,004 shares of the company’s stock worth $128,400,000 after buying an additional 1,121,497 shares during the last quarter. Norges Bank bought a new position in shares of Apellis Pharmaceuticals in the fourth quarter worth approximately $54,164,000. Finally, Morgan Stanley grew its holdings in shares of Apellis Pharmaceuticals by 112.6% during the third quarter. Morgan Stanley now owns 1,608,996 shares of the company’s stock valued at $61,206,000 after buying an additional 852,331 shares during the last quarter. 96.29% of the stock is currently owned by hedge funds and other institutional investors.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).